Image

Impact of Different Doses and Routes of Exogenous Progesterone Administration on Endometrial Receptivity Parameters

Recruiting
18 - 35 years of age
Female
Phase 4

Powered by AI

Overview

After so many years conducting artificial endometrial preparation cycles for embryo transfer, there is no clear indication about which is the optimal dose of exogenous progesterone in this scenario to optimize the outcome. Taking into account that the luteal phase can be controlled by measuring serum P levels (not done until now), the next step is to find out which is the best dose and route of administration of exogenous progesterone for luteal phase in artificial cycles.

Therefore, the aim of this experimental study is to compare the endometrial function and structure, as well as the serum P levels according to the use of different types of exogenous progesterone available on the market depending on their doses and route of administration (vaginal, subcutaneous or intramuscular). The endometrial receptivity status will be compared in the different artificial cycles with the one observed in a natural cycle, without exogenous progesterone (only the endogenous one) as a control group.

Endometrial receptivity will be analysed by means of endometrial function and structure, but not by pregnancy outcome as in this study an embryo cannot be replaced in the uterus because an endometrial biopsy needs to be done to do this type of research.

Eligibility

Inclusion Criteria

All women with no history of infertility who agree to participate in the study:

  1. Age: 18-35 years old, both inclusive
  2. Regular menstrual cycles
  3. In good health and not suffering from any mental or medical condition(s) that would preclude participation in the study.

Exclusion Criteria

        Subjects who meet one or more of the following will not be considered eligible to
        participate in the pilot study:
          1. Simultaneous participation in other clinical studies that, at the researcher's
             criteria, could interfere with the results of this study.
          2. Taking oral contraceptives in the three months prior to signing informed consent.
          3. Presence of uterine pathology (submucosal or intramural myomas >4 cm deforming cavity,
             endometrial polyps or müllerian anomalies) or adnexal pathology (communicating
             hydrosalpinx).
          4. Background of thrombosis, breast cancer, systemic diseases.
          5. Those unable to comprehend the investigational nature of the proposed study.

Study details

Infertility, Female, ENDOMETRIAL RECEPTIVITY

NCT04499131

Instituto Valenciano de Infertilidad, IVI VALENCIA

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.